Table 2 Intracranial response and systemic response in patients with NSCLC and brain metastases in the osimertinib group or osimertinib plus RT group
| Â | Intracranial response (RANO criteria) | Systemic response (RECIST v1.1) | ||
|---|---|---|---|---|
Osimertinib alone (n = 40) | Osimertinib + RT (n = 21) | Osimertinib alone (n = 40) | Osimertinib + RT (n = 21) | |
Objective response, n (%) | 17(42.5%) | 8(38.1%) | 7(17.5%) | 6(28.5%) |
 P value | 0.740 |  | 0.341 |  |
Disease control rate, n (%) | 38(95.0%) | 21(100.0%) | 37(92.5%) | 19(90.5%) |
 P value | 0.541 |  | 1.000 |  |
Best overall response, n (%) | ||||
 Complete response | 3(7.5%) | 2(9.5%) | 0 | 0 |
 Partial response | 14(35.0%) | 6(28.6%) | 7(17.5%) | 6(28.6%) |
 Stable disease | 21(52.5%) | 13(61.9%) | 30(75.0%) | 13(61.9%) |
 Progressive disease | 2(5.0%) | 0 | 3(7.5%) | 2(9.5%) |